Position in AZN
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$909,416,130
New position
Shares Held
4,611,176
first reported quarter
Ownership
0.297%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 99.8824594853894.ToString("F0")%
Shared 0.ToString("F0")%
None 0.11754051461058959.ToString("F0")%
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Capital Research Global Investors holds $39,059,483,079 across 9 Drug Manufacturers - General names. AZN ranks #6 (2.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
24,632,647 | $22,656,369,731 | |
| 2 | ABBV |
AbbVie Inc.
|
31,254,786 | $6,797,603,407 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
27,127,533 | $3,780,764,274 | |
| 4 | AMGN |
Amgen Inc
|
6,955,345 | $2,447,238,138 | |
| 5 | JNJ |
Johnson & Johnson
|
8,739,988 | $2,136,402,666 | |
| 6 | AZN |
Astrazeneca PLC
This page
|
4,611,176 | $909,416,130 | |
| 7 | MRK |
Merck & Co., Inc.
|
2,061,571 | $247,986,375 | |
| 8 | SNY |
Sanofi
|
1,661,837 | $80,067,306 |
All Filings in AZN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $909,416,130 | 4,611,176 | Shares | Defined | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||